New Self-Amplifying RNA vaccine shows promise in massive COVID-19 trial

NCT ID NCT05012943

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new type of COVID-19 vaccine called ARCT-154, which uses self-amplifying RNA technology to potentially provide stronger protection. Nearly 20,000 adults in Vietnam, including those with health conditions, received the vaccine or a placebo. Researchers measured safety, immune responses, and how well the vaccine prevented COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 VACCINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hanoi Medical University

    Hanoi, Hanoi, 00000, Vietnam

  • Military Medical University

    Hanoi, Hanoi, 00000, Vietnam

  • Pasteur Institute

    Ho Chi Minh City, Ho Chi Minh, 00000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.